Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)CAN1012 Combined With PD-1 in Patients With Solid Tumors
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Canwell Biotech Limited
- Target Recruit Count
- 71
- Registration Number
- NCT06410703
- Locations
- 🇨🇳
Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
Intratumoral CAN2109 in Subjects With Solid Tumors
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Canwell Biotech Limited
- Target Recruit Count
- 27
- Registration Number
- NCT06332430
- Locations
- 🇨🇳
Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Canwell Biotech Limited
- Target Recruit Count
- 27
- Registration Number
- NCT05580991
- Locations
- 🇨🇳
Canwell Biotech Limited, Guangzhou, Guangdong, China
News
No news found